1. Scrip

Merck & Co.’s Big Ambition To ‘Democratize’ PCSK9s

 
• By Jessica Merrill

Phase III studies testing the oral PCSK9 inhibitor MK-0616 for high cholesterol will begin in the second half of the year and include a broad program enrolling primary and secondary prevention patients.

go big
Merck & Co. is planning a big Phase III program for its oral PCSK9 inhibitor • Source: Shutterstock

Merck & Co., Inc. is moving aggressively to bring the first oral PCSK9 inhibitor to market and outlined an ambitious late-stage clinical trial program for MK-0616 during an investor event at the American College of Cardiology annual meeting on 6 March.

Merck is looking to develop MK-0616 for a broad audience, and with oral administration, the company believes the drug could be the first PCSK9 inhibitor to overcome the market access restrictions payers have put in

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.